Figure 7.

Crizotinib synergizes with cisplatin to suppress the subcutaneous xenograft growth of ovarian cancer in nude mice. A2780 cells (2 × 10⁶ in 100 μl of medium) were injected subcutaneously in each mouse under the axillia. When the subcutaneous tumors were approximately 0.3 × 0.3 cm² (two perpendicular diameters), mice were randomized into four groups, and were injected intraperitoneally with vehicle alone (20% hydroxypropyl-β-cyclodextrin), crizotinib alone (50 mg/kg), cisplatin alone (2 mg/kg), or a combination of crizotinib and cisplatin every four days. The body weights of mice and tumor volume were monitoring every day. In the end of the experiment, tumor tissue was excised from the mice after anaesthetized and weighted. The original tumors (A), tumor volume (B), tumor weight (C), body weight (D) and summary data (E) were shown. The values presented are the means ± SD for each group. Statistical analysis of the difference between two groups is performed with Student’s t-test. CRI: Crizotinib; DDP: Cisplatin. *P<0.05 and **P<0.01 CRI+DDP vs. corresponding control.